These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22331493)

  • 1. Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses.
    Muenyi CS; Pinhas AR; Fan TW; Brock GN; Helm CW; States JC
    Toxicol Sci; 2012 May; 127(1):139-49. PubMed ID: 22331493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin plus sodium arsenite and hyperthermia induces pseudo-G1 associated apoptotic cell death in ovarian cancer cells.
    Muenyi CS; Trivedi AP; Helm CW; States JC
    Toxicol Sci; 2014 May; 139(1):74-82. PubMed ID: 24519527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC).
    Muenyi CS; States VA; Masters JH; Fan TW; Helm CW; States JC
    J Ovarian Res; 2011 Jun; 4():9. PubMed ID: 21696631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.
    Pestell KE; Hobbs SM; Titley JC; Kelland LR; Walton MI
    Mol Pharmacol; 2000 Mar; 57(3):503-11. PubMed ID: 10692490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.
    Bhatt M; Ivan C; Xie X; Siddik ZH
    Oncotarget; 2017 Feb; 8(7):10905-10918. PubMed ID: 28038466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts.
    Yunmbam MK; Guo Y; Miller MR; Yu JJ
    Oncol Rep; 2004 Apr; 11(4):833-8. PubMed ID: 15010881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.
    Bagnoli M; Balladore E; Luison E; Alberti P; Raspagliesi F; Marcomini B; Canevari S; Mezzanzanica D
    Mol Cancer Ther; 2007 Feb; 6(2):762-72. PubMed ID: 17308072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cells.
    Li B; Gao Y; Rankin GO; Rojanasakul Y; Cutler SJ; Tu Y; Chen YC
    Cancer Lett; 2015 Jan; 356(2 Pt B):418-33. PubMed ID: 25304379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
    Song K; Li Z; Seth P; Cowan KH; Sinha BK
    Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
    Yan X; Fraser M; Qiu Q; Tsang BK
    Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
    Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
    J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
    Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
    J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged wild-type p53 protein accumulation and cisplatin resistance.
    Yazlovitskaya EM; DeHaan RD; Persons DL
    Biochem Biophys Res Commun; 2001 May; 283(4):732-7. PubMed ID: 11350044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines.
    Brown R; Clugston C; Burns P; Edlin A; Vasey P; Vojtĕsek B; Kaye SB
    Int J Cancer; 1993 Oct; 55(4):678-84. PubMed ID: 8406999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation.
    Xie X; He G; Siddik ZH
    Mol Cancer Res; 2017 Mar; 15(3):328-339. PubMed ID: 28031409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.
    Kulshrestha A; Katara GK; Ginter J; Pamarthy S; Ibrahim SA; Jaiswal MK; Sandulescu C; Periakaruppan R; Dolan J; Gilman-Sachs A; Beaman KD
    Mol Oncol; 2016 Jun; 10(6):789-805. PubMed ID: 26899534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.